Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity

NCT00947284
View directory record Official record
Conditions
Healthy
Interventions
nalbuphine plus naloxone, nalbuphine plus saline, naloxone plus saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 22, 2026, 2:11 AM EDT
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Recruiting Phase 3 Interventional

Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases

NCT06173401
View directory record Official record
Conditions
Spinal Metastases
Interventions
Single-fraction spine SRS, Multi-fraction spine SRS
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Single Arm on the Tolerability of Weekly Nab-paclitaxel

NCT01702844
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nab-Paclitaxel
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Healthy Adolescent Transitions (HAT)

NCT03194672
View directory record Official record
Conditions
Pregnancy Prevention, Life Skill Development
Interventions
Healthy Adolescent Transitions (HAT) program
Behavioral
Lead sponsor
Jack Stevens
Other
Eligibility
14 Years to 19 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Not applicable Interventional

Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

NCT00250081
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Tendon transfer, Botulinum Toxin injections in Upper Extremity, Regularly ongoing therapy
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional

MOSAIC (MOthers' AdvocateS In the Community) for Pregnant Women and Mothers of Children Under 5 With Experience of Intimate Partner Violence (MOSAIC Plus) Open Trial

NCT05968534
View directory record Official record
Conditions
Intimate Partner Violence, Depression, Posttraumatic Stress Symptom
Interventions
MOSAIC Plus
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Not listed Not applicable Interventional

Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams

NCT02167009
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
Tampa General Hospital
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 22, 2026, 2:11 AM EDT
Not listed Not applicable Interventional

e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions

NCT02087293
View directory record Official record
Conditions
Diabetes, Depression, Insomnia, Hypertension
Interventions
Intervention arm - automated call and phone-based pharmacist counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
38,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 22, 2026, 2:11 AM EDT
Recruiting Phase 4 Interventional

Endogenous Opioid Response to Injections

NCT06666621
View directory record Official record
Conditions
Low Back Pain, Zygapophyseal Joint Arthritis
Interventions
Normal saline infusion, Naloxone infusion
Drug
Lead sponsor
Middle Tennessee Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 22, 2026, 2:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Smart Phone as a Screening and Evaluation Tool to Identify Knee Valgus During Dynamic Activities

NCT02167399
View directory record Official record
Conditions
Leg Injuries
Interventions
Not listed
Lead sponsor
Mitchell Selhorst
Other
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493
View directory record Official record
Conditions
Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer
Interventions
Venetoclax, Ibrutinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional

Effects of Whole Body Vibration on Quadriceps Function, Landing Biomechanics, and Performance in Individuals With ACL Reconstruction

NCT07681193
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Tear, ACL Injury, ACL Tear, Biomechanical Phenomena
Interventions
Whole body vibration (WBV), Sham Whole body vibration
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

NCT06563804
View directory record Official record
Conditions
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
Interventions
S227928, Venetoclax
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
VS-6766, Abemaciclib, Fulvestrant
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Flavored on!® Nicotine Pouch Products on Smoking Behaviors: a SMART Study

NCT06072547
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), Access to Original on! 4mg nicotine pouches, Non-Flavored then complete flavor on! nicotine pouches
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

NCT02181634
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Nab-Paclitaxel and Gemcitabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional

Effects of Reduced Environmental Stimulation on Eating Disorders

NCT02801084
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Reduced environmental stimulation
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 22, 2026, 2:11 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment

NCT07742449
View directory record Official record
Conditions
Cancer, Pain, Pain Management, Chronic Pain, American Indian or Alaska Native
Interventions
Empowered Relief
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 2:11 AM EDT